Its other home consumption products such as ghee and butter have already seen an increase amid the lockdown. Owing to such strong revival hopes, the company aims to achieve pre-COVID business levels within the next few months.

D-Street has a lot to face this morning. Some of the major reasons are the rising anxiety regarding resurge of coronavirus cases and geopolitical tensions. Further, IMF projected India’s GDP to contract by 4.5 per cent in FY21 confirming weakness in growth.

The level of 10,277 is likely to act as an immediate support level and any move below this level could result in another round of selling. In that case, Nifty may slip towards 10,140 levels. Stocks in news: Asian Granito India, TCS, Bharti Infratel, Andhra Paper.

On Wednesday, JM Financial Private Equity announced that it had completed its proposed investment of Rs 40 crore into Coimbatore-based co-living operator, Isthara Parks Private Limited. The investment was completed in two tranches between July 2019 and June 2020.

The banking benchmark index, Bank Nifty, opened today’s trading session with an upside gap but failed to show a follow-through move and tumbled down. As a result, it formed a bearish engulfing candlestick pattern on the daily scale.

The stock of Berger Paints India Limited has given a downward sloping trendline breakout, formed by connecting swing highs from April 2020. This breakout was confirmed by the above 50-day average volumes.

Markets remained volatile during today's trading session, ahead of the expiry of June series derivative contracts tomorrow. Erasing the day gains, Sensex slipped by over 800 points from its day high on Wednesday, to close at 34,868.98 which is 561.45 points or 1.58 per cent lower than its previous close, while Nifty fell by 165.70 points or 1.58 per cent to settle at 10,305.30.

ICRA and CARE has downgraded the ratings for the aforesaid instrument as (ICRA) D and CARE D (Single D) took into account the net loss of Rs 16,418 crore reported by the company in FY20 as well as the CRAR of 8.5 per cent. 

Zydus Cadila on Wednesday announced that the company has received an approval from United States Food and Drug Administration (USFDA) to market Meclizine Hydrochloride tablets. 

Vaishali Pharma has forayed into the domestic pharmaceutical market by launching two antifungal brands under dermatology therapy segment.